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Abstract
Objectives
To evaluate the risk of complication in hospitalized chronic hepatitis C (CHC), patients with
cannabis use disorder (CUD).
Methods
We conducted a retrospective study using the nationwide inpatient sample (NIS), and included
31,623 patients (age 15-54) with a primary international classification of diseases, ninth
revision (ICD-9) diagnosis for CHC and grouped by co-diagnosis of CUD (1101, 3.5%). Logistic
regression model adjusted for confounders was used to evaluate the odds ratio (OR) of CUD and
complications during CHC hospitalization.
Results
Comorbid CUD was prevalent in males (73.2%), Caucasians (59.9%), and from low-income
families (65.7%). The most prevalent complications in patients with CUD were ascites (44.9%),
alcoholic cirrhosis (42.8%) and non-alcoholic cirrhosis (41.1%). The odds of association for
hepatic encephalopathy was 2.2 times higher (95% CI 1.477-3.350) in 2.8% CHC inpatients with
CUD compared to 1.2% non-CUD inpatients. Hepatic encephalopathy had higher odds of
association with a male by 1.4 times (95% CI 1.094-1.760), and African American by 1.7 times
(95% CI 1.293-2.259).
Conclusion
CUD is significantly associated with 122% increased likelihood for hepatic encephalopathy that
may worsen overall hospitalization outcomes in CHC patients. Hence, we need to consider the
complex relationship between CUD and CHC and manage them optimally to improve the
health-related quality of life.
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Introduction
Cirrhosis is the chronic liver disease in critical stage caused by the hepatitis C virus (HCV)
infection. Risk factors for fibrosis progression in cirrhosis include male gender, higher age at the
time of HCV infection, duration of infection, alcohol consumption, and co-infection with
human immunodeficiency virus (HIV) [1].
Cannabis is widely used for medicinal and recreational purposes. It consists of about 60
cannabinoid compounds, including delta-9-tetrahydrocannabinol (delta-9-THC), which is the
most active component of cannabis [2]. In the US, the prevalence of cannabis use among adults
is estimated to be four percent. It increases in specific population subgroups, including 18 to
29-years old individuals [3]. Many studies suggest that cannabinoids have an important, yet
undefined, role in hepatic fibrosis as cannabinoid CB1 receptor inactivation promotes the
development of fibrosis while cannabinoid CB2 receptor activation exerts an inhibitory effect
[4-5].
The prevalence of cannabis use among adults infected with HCV has not been thoroughly
studied, and there is a lack of epidemiologic studies to evaluate the effect of cannabis on liver
fibrosis [6]. A study by Hezode C et al. in 270 patients with chronic hepatitis C (CHC) found that
daily cannabis smoking is significantly associated with progression of fibrosis during CHC [6].
Patients with chronic health conditions who consume cannabis frequently were found to have
more severe fibrosis/steatosis compared to the occasional or non-consumer of cannabis [7].
Myriad of evidence indicates that the endocannabinoid (EC) system plays a vital role in various
liver diseases. It includes viral hepatitis, non-alcoholic fatty liver disease, alcoholic liver
disease, hepatic encephalopathy, and autoimmune hepatitis [7]. EC has an impact on
metabolism, secretion of hormones regulating appetite and satiety, lipogenesis, adipogenesis,
and obesity. Certain ECs in plasma and liver tissues are elevated in cases of human chronic
liver disease and thus correlate with disease severity [7].
As per the past literature, cannabis use is associated with increased risk of fibrosis in CHC
patients, which may lead to cirrhosis. There are no studies to assess the prevalence and risk of
complications to cirrhosis in CHC patients abusing or dependent on cannabis. Our main goals
for this inpatient study are to delineate the demographic characteristics of CHC patients and to
evaluate the risk of complication including esophageal varices, ascites, portal hypertension,
alcoholic and non-alcoholic cirrhosis, and hepatic encephalopathy.
Materials And Methods
Data source
We performed a retrospective cohort study using the nationwide inpatient sample (NIS)
database from January 2010 to December 2014 from the healthcare cand utilization project
(HCUP) [8]. The NIS provides discharge patient records from a 20% sample of 4,400 hospitals
across 45 states in the US [8], and when discharge weights are applied to the data, the result is
for a nationally representative sample [9]. Diagnostic information in the NIS is detected using
the international classification of diseases, ninth revision (ICD-9) codes.
Inclusion criteria and outcome variables
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We included patients (age 15-54) with a primary ICD-9 discharge diagnosis for CHC (070.44 or
070.54). Co-diagnosis of cannabis use disorder (CUD), including cannabis abuse or dependence
was identified using the ICD-9 codes 304.30, 304.31, 304.32, 305.20, 305.21, or 305.22 [10].
Patients with co-diagnosis of cannabis abuse and in partial or complete remission were not
included in the CUD cohort. We excluded patients above 54 years, as 90th percentile of the
population that abuse cannabis is in 15-54 years age group [10].
Demographic variables studied included age group (15-24, 25-34, 35-44, 45-54), gender (male
or female), and race (Caucasian, African American, Hispanic, or other) [9]. The comorbid risk
factors for CHC and fibrosis were based on past literature [1] and identified using ICD-9
diagnosis codes and HCUP clinical classification software (CCS) codes [9,11]. Complications
during hospitalization for CHC were identified using the ICD-9 or CCS diagnosis codes [11]
namely, esophageal varices, ascites, portal hypertension, alcoholic and non-alcoholic cirrhosis,
and hepatic encephalopathy.
Statistical analysis 
We compared non-CUD and CUD cohorts in CHC inpatient population using bivariate analysis
to evaluate the differences in terms of demographics, comorbid risk factors, and hospitalization
complications using the Pearson’s chi-square test. Later, we utilized multivariable logistic
regression model adjusted for demographics and comorbid risk factors to evaluate the odds
ratio (OR) of CUD as an associated factor for complications during CHC hospitalization. All
statistical analyses set a priori at <0.05 were conducted in the statistical package for the social
sciences (SPSS) version 25 (IBM Corp., Armonk, NY).
Ethical approval
Individual identifiers [9] were used to protect patient identity and other clinical information.
The use of NIS under the HCUP does not require approval from an institutional review board as
the NIS is a publicly available de-identified database [8].
Results
We analyzed a total of 31,623 hospitalizations for CHC, and comorbid CUD was seen in 1101
inpatients (3.48%). Majority of the patients in the total study population were middle-aged
adults, aged 45-54 years (total 85%, 85.2% in non-CUD, and 79.1% in CUD group). CUD was
seen in a higher proportion of young adults, aged 25-34 years (8.2% CUD vs. 3% total).
Comorbid CUD was prevalent in males (73.2%), Caucasians (59.9%), and from low-income
families below the 50th percentile (65.7%), and a similar pattern was seen in the total CHC
inpatients as shown in Table 1.
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Variable Non-CUD (%) CUD (%) Total (%) P value
Inpatients 30522 1101 31623 -
Age at admission
15 – 24 years 0.6 0 0.6
<0.001
25 – 34 years 2.8 8.2 3.0
35 – 44 years 11.4 12.7 11.4
45 – 54 years 85.2 79.1 85.0
Sex
Male 67.0 73.2 67.2
<0.001
Female 33.0 26.8 32.8
Race
Caucasian 59.2 59.9 59.3
<0.001
African American 10.9 8.5 10.8
Hispanic 23.8 24.6 23.8
Other 6.1 7.0 6.1
Median household income, in percentile
Below 50th 65.7 67.2 65.7
0.299
Above 50th 34.3 32.8 34.3
Comorbid risk factors
HIV/AIDS 2.7 3.8 2.7 0.022
Hepatitis B 2.7 3.7 2.8 0.049
Alcohol use disorder 35.9 55.0 36.6 <0.001
Diabetes 24.6 18.6 24.3 <0.001
Obesity 10.0 8.5 10.0 0.086
TABLE 1: Chronic hepatitis C inpatients by cannabis use disorder
CUD: cannabis use disorder; HIV/AIDS: human immunodeficiency virus/acquired immunodeficiency syndrome.
Alcohol use disorder was the most prevalent comorbid risk factor. There was a statistically
significant difference seen between CUD and non-CUD inpatients (55% vs. 35.9%, P <0.001).
Next, diabetes was seen in 24.3% total CHC inpatients but was seen in a lower proportion of
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CUD inpatients (18.6% vs. 24.6%, P <0.001). Co-diagnoses of human immunodeficiency
virus/acquired immunodeficiency syndrome (HIV/AIDS) and hepatitis B were seen in a higher
proportion of CUD than non-CUD and were statistically significant.
The most prevalent complications during inpatient management of CHC in patients with CUD
were ascites (44.9%), alcoholic cirrhosis (42.8%) and non-alcoholic cirrhosis (41.1%). In the
adjusted logistic regression model, we found that there was statistically no significant odds of
association of esophageal varices, ascites, and non-alcoholic cirrhosis in CHC inpatients with
CUD compared to non-CUD. The odds of association for hepatic encephalopathy was 2.2-fold
higher (95% CI 1.477-3.350, P <0.001) in 2.8% CHC inpatients with CUD compared to 1.2% non-
CUD inpatients as shown in Table 2.
Variable Non-CUD (%) CUD (%) OR 95% CI P value
No complication - - Reference
Esophageal varices 0.5 0.5 0.83 0.326 – 2.093 0.686
Ascites 45.0 44.9 1.03 0.906 – 1.165 0.676
Portal hypertension 34.5 27.4 0.71 0.620 – 0.820 <0.001
Alcoholic cirrhosis 33.7 42.8 0.83 0.708 – 0.977 0.025
Non-alcoholic cirrhosis 50.5 41.1 1.13 0.976 – 1.304 0.102
Hepatic encephalopathy 1.2 2.8 2.22 1.477 – 3.350 <0.001
TABLE 2: Association with complication in chronic hepatitis C inpatients with
cannabis use disorder
The proportions between non-CUD and CUD groups were obtained by cross-tabulation. Odds ratio and the 95% confidence intervals
were generated using the logistic regression model.
CUD: cannabis use disorder; OR: odds ratio; CI: confidence interval.
Hepatic encephalopathy had higher odds of association with male gender by 1.4 times (95% CI
1.094-1.760, P = 0.007), African American by 1.7 times (95% CI 1.293-2.259, P <0.001) and those
from low-income families by 1.5 times (95% CI 1.218-1.868, P <0.001). Among the
comorbidities, hepatic encephalopathy and CUD had higher odds of association by 2.4 times
(95% CI 1.575-3.579, P <0.001). The predictors of hepatic encephalopathy in CHC inpatients are
shown in Table 3.
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Variable Odds Ratio
95% Confidence Interval
P value
Lower Upper
Age at admission
15 – 24 years <0.001 <0.001 - 0.999
25 – 34 years <0.001 <0.001 - 0.990
35 – 44 years 1.072 0.772 1.489 0.678
45 – 54 years Reference
Sex
Male 1.387 1.094 1.760 0.007
Female Reference
Race
Caucasian Reference
African American 1.709 1.293 2.259 <0.001
Hispanic 0.492 0.356 0.679 <0.001
Other 0.459 0.247 0.851 0.013
Median household income, in percentile
Below 50th Reference
Above 50th 1.508 1.218 1.868 <0.001
Comorbid risk factors
No comorbid risk factor Reference
HIV/AIDS 1.044 0.538 2.023 0.899
Hepatitis B 0.489 0.201 1.188 0.114
Alcohol use disorder 0.804 0.642 1.006 0.057
Cannabis use disorder 2.374 1.575 3.579 <0.001
Diabetes 0.983 0.766 1.262 0.893
Obesity 0.691 0.457 1.043 0.079
TABLE 3: Predictors of hepatic encephalopathy in chronic hepatitis C inpatients
HIV/AIDS: human immunodeficiency virus/acquired immunodeficiency syndrome.
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Discussion
The factors influencing CHC are essential to understand for patient management. The impact of
alcohol consumption in CHC patients has been studied in the past [12-14], and abstaining from
alcohol use is of great importance for CHC. Many studies found that cannabis use is a risk factor
for disease progression in patients with CHC [6,15-17]. Daily cannabis use was significantly
associated with the presence of moderate to severe fibrosis in patients with CHC [1,6]. These
patients should be counseled to reduce or abstain from cannabis use.
Liver fibrosis is a common pathological consequence of viral hepatitis, including CHC [18-19].
Liver fibrosis results in progressive distortion of the normal hepatic architecture due to the
continuous replacement of healthy liver tissue with the extracellular matrix. These continuous
changes can evolve into cirrhosis [20]. There are severe complications of liver cirrhosis, which
include hepatic encephalopathy. These complications increase the risk of mortality in patients
with chronic liver disease [20]. The cannabinoid receptors CB1 and CB2 have been proved to
have the fibrogenic influence of cannabis. The inactivation of cannabinoid CB1 receptors by
genetic or pharmacological approaches prevented fibrogenesis through downregulation of
transforming growth factor (TGF) β1 levels and reduction of fibrogenic cell accumulation [5].
The most prevalent risk factors in CHC inpatients were alcohol use disorder, diabetes,
HIV/AIDS, and obesity. Also, alcohol use disorder was prevalent in CHC inpatients with CUD.
Concurrent use of cannabis and alcohol is not uncommon, and as moderate/heavy alcohol
users may substitute alcohol with cannabis after diagnosis of CHC [12-14], it is essential to
understand the relationship between chronic cannabis use or CUD and CHC.
Ascites, alcoholic cirrhosis, and non-alcoholic cirrhosis were the most prevalent complications
during inpatient management of CHC. There was no statistical significance between the
association of these complications in CHC patients with CUD when compared with non-CUD
cohort. The probability of association of hepatic encephalopathy was two-fold higher in
inpatients with CUD compared to non-CUD inpatients. Hepatic encephalopathy is a late-stage
complication seen in end-stage liver disease and is caused when the liver is unable to remove
toxins from the blood and causes a loss of brain function [21]. The liver damage can cause
sudden hepatic encephalopathy. In most cases, it occurs in individuals with chronic liver
disease, but in some cases, hepatic encephalopathy occurs in people unaware of their liver
problems [21]. There are no past studies to evaluate the causal relationship between hepatic
encephalopathy and cannabis abuse in CHC patients, and hence, our findings could seed for
future studies in this area.
Also, African Americans are found to be 1.7 times more likely to be associated with hepatic
encephalopathy as other racial groups. A recent study also supported this finding and
concluded that hepatic encephalopathy among hospitalized adults has a significantly higher
risk of in-hospital mortality in African Americans as compared to other racial groups [22].
Among comorbid risk factors, we found CUD to increase the likelihood of hepatic
encephalopathy by 2.4 times in CHC inpatients. This could be explained by a study that found
that in end-stage liver disease, the endocannabinoid system has been shown to contribute to
hepatic encephalopathy and vascular effects [21].
The first limitation of this study is that due to the administrative nature of the NIS, the data
regarding the cannabis dose, route of intake, and duration was not obtainable to explicate the
underlying pathology. So, were not able to measure a causal association between CUD, CHC,
and hepatic encephalopathy. Also, we have included patients that are hospitalized for CHC, and
do not have information about the clinical status of the patients due to the administrative
nature of the NIS database lacking patient-level clinical information. There may be
underreporting of comorbid risk factors and complications due to the differences in recording
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the conditions by ICD-9 coding. However, the fundamental strength of our study is a large
sample size of CHC-related hospitalizations that enables us to evaluate the risk of
complications in patients with CUD. Due to the nationally representative study population, our
findings have external validity.
Conclusions
Cannabis use is rising with its growing accessibility among the US population due to
snowballing legalization, resulting in apprehensions for problematic cannabis use including
cannabis dependence and abuse. After controlling for comorbid risk factors, CUD is
significantly associated with 122% increased likelihood for hepatic encephalopathy that may
worsen overall hospitalization outcomes in CHC patients. It is important to consider the
complex relationship between problematic cannabis use (abuse or dependence) and CHC and
manage them optimally to improve the health-related quality of life.
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